Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...
The switch from autologous to off-the-shelf products is a key step in taking the modality into the mainstream, driving a surge in allogeneic cell therapy R&D activity. NK (natural killer ...
The first clinical program to go over involves the use of ImmunityBio's CAR-NK cell therapy CD19 t-haNK, which is being tested in the ongoing phase 1 QUILT 106 study. As I alluded to above ...
Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback